HROW
HROW
NASDAQ · Pharmaceuticals

Harrow Inc

$36.11
+0.91 (+2.59%)
As of Mar 25, 1:40 PM ET ·
Financial Highlights (FY 2026)
Revenue
207.42M
Net Income
-18,163,334
Gross Margin
75.3%
Profit Margin
-8.8%
Rev Growth
+40.2%
D/E Ratio
3.15
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 75.3% 75.3% 63.9% 63.9%
Operating Margin 4.4% 4.0% 23.6% 21.0%
Profit Margin -8.8% -8.3% 15.6% 16.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 207.42M 147.98M 753.50M 775.29M
Gross Profit 156.25M 111.47M 481.22M 495.14M
Operating Income 9.17M 5.89M 178.06M 162.96M
Net Income -18,163,334 -11,662,267 117.60M 129.68M
Gross Margin 75.3% 75.3% 63.9% 63.9%
Operating Margin 4.4% 4.0% 23.6% 21.0%
Profit Margin -8.8% -8.3% 15.6% 16.7%
Rev Growth +40.2% +40.2% +23.8% +22.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 511.13M 511.13M 692.61M 691.25M
Total Equity 162.17M 162.17M 1.12B 1.10B
D/E Ratio 3.15 3.15 0.62 0.63
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 10.90M 7.39M 185.25M 214.55M
Free Cash Flow 80.89M 86.69M